Zydus Cadila Gets USFDA Nod for Skin Ointment, Stomach Ailment Drug

U.S. FDA Opens New Safety Review of RSV Treatments for Infants

The FDA Officially Blesses AI for Liver Drug Development

FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers

FDA Dye Tracker Raises Reformulation Pressure Across Food Brands

Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy

The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030

Brazil Expands Chemical Tax Breaks as India’s Crop Protection Industry Warns of a 25% Cost Increase

After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition

关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI

U.S. Congress Passes Bill Authorizing Tariffs of Up to 100% on Major Buyers of Russian Energy